Skip to main navigation
  • News & Investors

    News & Investors

    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact
  • Contact Us
Celsion
  • TECHNOLOGY
    • LTSL
    • TheraPlas
    • TheraSilence
  • PRODUCTS
    • ThermoDox
    • GEN-1
  • PIPELINE
    • Clinical Studies
    • Pre-clinical Programs
  • DISEASES
  • PUBLICATIONS
  • ABOUT US
    • Leadership
    • Board of Directors
    • Corporate Governance
Select Page

Press Releases

    Investor Relations

    • News & Investors
    • Press Releases
    • Financial Events
    • Scientific Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Analyst Coverage
    • Request Information
    • Investor FAQs
    • Investor Contact

Press Releases

Company News

Date Title and Summary Additional Formats
Toggle Summary Nov 8, 2021 Celsion Provides Update on its Application to Sell $1.5 Million of New Jersey Net Operating Losses
Application A pproval Will Further Extend Current Operating Runway to Over Three Years To date, through the New Jersey Technology Business Tax Certificate Transfer (NOL) Program ,   Celsion has r aised over $14 million in N on- D ilutive C apital LAWRENCEVILLE, N.J. , Nov.
View HTML
PDF Version
Toggle Summary Nov 8, 2021 Celsion Corporation’s GEN-1 IL-12 Program to be Featured at Cytokine-Based Cancer Immunotherapies Summit
Chief Science Officer Dr. Khursheed Anwer to also Participate in Two Panel Discussions LAWRENCEVILLE, N.J. , Nov. 08, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces that
View HTML
PDF Version
Toggle Summary Oct 15, 2021 Celsion Corporation Announces Time of Oral Presentation at International Vaccines Congress
Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual   P resentation Monday, October 18 at 7:30 a.m. Eastern Time LAWRENCEVILLE, N.J. , Oct. 15, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA mediated immunotherapy and
View HTML
PDF Version
Toggle Summary Oct 12, 2021 Celsion Corporation Announces Oral Presentation at International Vaccines Congress
Chief Science Officer Dr. Khursheed Anwer to D eliver V irtual   P resentation on Celsion’s O ngoing W ork with DNA-based V accines LAWRENCEVILLE, N.J. , Oct. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage development company focused on DNA mediated immunotherapy
View HTML
PDF Version
Toggle Summary Oct 11, 2021 Celsion GmbH Announces the Publication of an Article Reviewing the History of ThermoDox® Drug Development in Advanced Drug Delivery Reviews
Investigator-Sponsored Research with ThermoDox ®   Continues in Multiple Indications New Support for ThermoDox ® ’s P otential from the National Institutes of Health under a Cooperative Research and Development Agreement ZUG, Switzerland , Oct. 11, 2021 (GLOBE NEWSWIRE) -- Celsion   GmbH , a wholly
View HTML
PDF Version
Toggle Summary Oct 5, 2021 Celsion Corporation Adds Key Resources to its Vaccine Development Initiative and Clinical Trial Capabilities
LAWRENCEVILLE, N.J. , Oct. 05, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage development company focused on DNA-based immunotherapy and next-generation vaccines, announces the strengthening of its management team with a new hire and a promotion in its vaccine
View HTML
PDF Version
Toggle Summary Sep 30, 2021 Celsion to Present at Three Investment Conferences in October
LAWRENCEVILLE, N.J. , Sept. 30, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN), a clinical-stage company focused on DNA-based immunotherapy and next-generation vaccines, today announced that management will present at the following investment conferences in October: Chardan’s 5 th
View HTML
PDF Version
Toggle Summary Sep 17, 2021 Celsion and Hainan Poly Pharm Sign Agreement to Manufacture Celsion’s DNA-based Vaccine
  E xpands GEN-1 P rogram C ollaboration to Add   C linical and C ommercial B atches of I nvestigational V accine LAWRENCEVILLE, N.J. and HAINAN, China , Sept. 17, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN ) , a clinical-stage company focused on DNA-based immunotherapy and
View HTML
PDF Version
Toggle Summary Sep 2, 2021 Celsion Reports T-cell and B-cell Response from In Vivo Studies with its PLACCINE DNA Vaccine Platform
Results Indicate Induction of Adaptive Immune Response Against SARS-CoV-2 Company Plans Additional Development Work to Further Optimize its Vaccine Platform Through Vector Compositions, Delivery Route, Dosing and Dosing Frequency, and Use of Molecular Adjuvant LAWRENCEVILLE, N.J. , Sept.
View HTML
PDF Version
Toggle Summary Aug 12, 2021 Celsion Corporation Reports Second Quarter 2021 Financial Results and Provides Business Update
Strong Balance Sheet Supports Focus i n Immuno-Oncology and on   Next-Generation Vaccine Initiative Conference Call Begins Today   at 11:00 a.m.   Eastern Time LAWRENCEVILLE, N.J. , Aug. 12, 2021 (GLOBE NEWSWIRE) -- Celsion Corporation (NASDAQ: CLSN) , a clinical-stage drug-development company
View HTML
PDF Version

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 2
  • Current page 3
  • Page 4
  • Page 5
  • …
  • Next page Next
  • Last page Last

    Shareholder Tools

    • Printed Materials
    • Email Alerts
    • Downloads
    • RSS
    • Print
    • Search

    • Facebook
    • LinkedIn
    • Twitter
    • RSS

Celsion
Home

Technology

Products

Pipeline

Disease

Publications

News & Investors

About Us

Careers

Privacy Policy

LinkedIn

    ThermoDox is a registered trademark of Celsion Corporation.
    TheraPlas and TheraSilence are trademarks of Celsion Corporation.
    Avastin is a registered trademark of Genentech, Inc.
    Copyright © 2022 Celsion Corporation. All rights reserved.

    • Twitter
    • Facebook
    • LinkedIn
    Share This
    • Twitter
    • Google+
    • Facebook
    • LinkedIn